NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Mesoblast Limited (MESO) Stock Analysis

Mesoblast Limited (MESO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MESO

$17.32

+$0.18 (+1.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MESO with… →

MESO Key Statistics

As of Sep 4, 2026
Trading
Open
$17.04
Previous Close
$17.14
Day's Range
17.03–17.34
52-Week Range
13.05–21.50
Volume
93.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.82
Valuation
Market Cap
$2.25B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
38.07
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.70
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.45
Financials (FY)
Revenue (FY)
$17.20M+191.39%
Net Income (FY)
−$102.14M
Profit marginThe share of revenue left as profit after all costs and taxes.
−47.82%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
129.85M
1-Year Return
+28.11%
Dividend and dates
Avg Volume
228.45K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MESO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−3.99%
2025−8.89%
2024+800.00%
2023−62.20%
2022−39.37%
2021−43.46%
2020+15.20%
2019+78.88%
2018−29.45%
2017+9.16%
2016 (partial year)+25.00%

As of September 4, 2026.

MESO Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$17.20M−$102.14M−593.9%
2024$5.90M−$87.96M−1490.3%
2023$7.50M−$81.89M−1091.7%
2022$10.21M−$91.35M−894.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$17.20M$12.07M−$62.44M−$102.14M−593.9%
2024$5.90M$5.90M−$57.97M−$87.96M−1490.3%
2023$7.50M$7.50M−$69.29M−$81.89M−1091.7%
2022$10.21M—−$81.11M−$91.35M−894.6%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

MESO Valuation vs Biotechnology Median

Median of 656 stocks
MetricMESOBiotechnology medianvs median
P/S ratio18.7015.2623% above
Profit margin−47.82%0.00%47.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Mesoblast Limited (MESO) at $2.25B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 108 employees.

Over the past 52 weeks the price has ranged from $13.05 to $21.50. The most recent close on file for MESO is $17.32, dated September 4, 2026. That is +$0.18 (+1.05%) against the previous close. The latest close sits 32.72% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $17.20M. Against the prior fiscal year total of $5.90M, that is a change of +191.39%. The same year closed with a net loss of $102.14M. Profit margin runs at −47.82%. That is 47.8 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.45.

Across the 4 fiscal years on file, revenue moves from $10.21M in 2022 to $17.20M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 38.07. Measured against sales, the shares trade at 18.7 times revenue. On price-to-sales that is 22.54% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +28.11%. Measured over 10 years, that is +5.73% a year compounded. Beta against the wider market is reported at 0.82. Daily returns over the trailing 10 years annualize to a volatility of 93.81%.

Growth & Income

No dividend is on file for MESO.

Across the complete calendar years on file, 2024 returned +800.00% and 2023 returned −62.20%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is −3.99%.

Peer Comparison

Mesoblast Limited (MESO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Mesoblast Limited MESO $2.25B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Mesoblast Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Mesoblast Limited

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Visit website →